Skip to main content
ARCT
NASDAQ Life Sciences

FDA Endorses Ammonia as Key Pediatric Endpoint; Arcturus Adds ARCT-2601 to Phase 2 Trial

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$13.8
Mkt Cap
$393.66M
52W Low
$5.5
52W High
$24.17
52W Position info
151% above low
Off High info
43% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ARCT has more than doubled off its 52-week low of $5.5.

Summary

Arcturus will add ARCT-2601 to its Phase 2 ARCT-810 trial after an FDA meeting, with dosing of 3-6 OTCD patients planned near year-end to assess safety, PK, and biomarkers. The FDA indicated ammonia is a key pediatric endpoint while glutamine may be acceptable for adults, prompting longer metabolic stability studies. The company also unveiled liver-focused preclinical programs for PKU and gout, with PKU data showing phenylalanine control in mice and primates. This follows the September 23 interim Phase 2 data for ARCT-810 and the myNEO acquisition, reinforcing the pipeline's momentum. The FDA's endpoint guidance de-risks the pediatric development path, a meaningful regulatory clarity for a company with a $394M market cap.

At the time of this announcement, ARCT was trading at $13.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $393.7M. The 52-week trading range was $5.50 to $24.17. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

ARCT - Latest Insights

ARCT
Nov 16, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.52
Real-time Price: $8.78 info
Change: +$0.260 (+3%) info
Market Cap: $253.062M info
ARCT
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.90
Real-time Price: $8.78 info
Change: -$1.12 (-11%) info
Market Cap: $253.062M info
ARCT
Nov 05, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.34
Real-time Price: $8.78 info
Change: -$0.560 (-6%) info
Market Cap: $253.062M info
ARCT
Sep 23, 2026, 4:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $8.78 info
Change: -$5.12 (-37%) info
Market Cap: $253.062M info
ARCT
Sep 23, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $8.78 info
Change: -$5.12 (-37%) info
Market Cap: $253.062M info